Cardiology Flashcards

(56 cards)

1
Q

Chest pain on normal coronaries

A

Microvascular dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment of severe mitral regurgitation

A

Reduce left ventricular volume:
Ace(arb), beta blocker, aldosterone inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Ascending aorta aneurysm requires repair

A

5.5 cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

SVT terminated by vagal maneuvers

A

Atrioventricular nodal reentrant tachycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cannon a waves

A

Dissociation of AV conduction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Widened QRS due to

A
  1. SVT with aberrancy
  2. Pre-excited tachycardia
  3. VT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Ventricular Tachycardia

A
  1. Positive in aVR
  2. QRS morphology concordant (all predominantly positive or negative) in precordial leads
  3. Exhibit extreme axis deviation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Severe mitral stenosis

A

Valva area < 1.5 cm2
Mitral gradient > 5-10 mmHg at normal heart rate
PASP > 50 mmHg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Beta blockers with mortality effects

A

Bisoprolol
Carvedilol
Metoprolol succinate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Acute limb ischemia

A

Paresthesia
Pain
Pallor
Pulselessness
Poikilothermia (coolness)
Paralysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HFpEF pathophysiology

A
  1. LV hypertrophy
    2, LV fibrosis
  2. Chronotropic incompetence
  3. Microvascular dysfunction
  4. Inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HFpEF

A

Elevated filling press
Structural abnormalities LVH, LAE
elevated BNP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

DDX from HFpEF

A
  1. Restrictive CMP
  2. Hypertrophic CMP
  3. Storage disease
  4. Pericardial disease
  5. Valvular heart disease
  6. Primary RV failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Causes of restrictive heart disease

A
  1. Amyloid
  2. Hemochromatosis
  3. Sarcoidosis
  4. Endomyocardial fibrosis
  5. Radiation/chemotherapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Comorbidities in HFpEF

A
  1. Htn
  2. Obesity
  3. DM/prediabtes
  4. Chronic kidney disease
  5. Afib
  6. Chronotropic incompetence (left ventricular strain)
  7. Decrease oxygen uptake
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chronotropic incompetence

A

the inability of the heart to increase its rate commensurate with increased activity or demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treatment HFpEF

A
  1. Diuretic (1)
  2. SGLT2 inhibitors (2a)
  3. ARNI (2b)
  4. MRA (2b)
  5. ARB (2b)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Heart Failure
Goal of diuretic

A

> 100-150 ml/hr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

CHF
Diuretic combination

A

Loop diuretic -double dose (2-2.5 x home diuretic divided into twice day(titrate q12-24hrs(max960mg/d)
Metalazone (low K, increamortality)
Acetazolamide (500 mg iv daily)
SGLT2 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Increase in creatinine and congestion improved

A

Metra M et al Circ Heart Failure 2012; 5:54

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cardiac sarcoidosis

A

FDG, PET, cMRI, endometrial biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Sarcoidosis

A

Dual isotope pet scanning (N-NH3 defects and matched F-FDG uptake)
Ammonia is perfusion.
FDG activity /metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Severe aortic stenosis

A

Vmax > 4 m/s or mean gradient > 40 mm Hg
Aortic valve area < 1 cm squared

24
Q

Murmur louder with standing

A

Hypertrophic cardiomyopathy

25
Type B dissection
IV beta blocker Nitroglycerin iv Pain control SBP 120 pulse 60
26
PVC BURDEN OF >10%
PVC induced cardiomyopathy
27
Pharmacologic testing in wheezing must avoid the following:
Adenosine Dipyridamole Regadenoson
28
CHF OBJECTIVES diuresis
After six hours 100-150 ml/hr
29
If creatinine goes up and decongestion occurs, ok hold diuretic
30
MINOCA INOCA ANOCA
Mi w/ non obstructive cad Ischemia w/ no obstructive cad Angina w/ non obstructive cad
31
Causes of MINOCA MI TO NON OBSTRUCTIVE CAD
Coronary embolism Coronary microvascular dysfunction Coronary spasm Coronary thrombosis Myocardial bridging Plaque rupture Spontaneous coronary dissection
32
Cardiac MRI HELPS w/ contrast
Myocardial edema Myocardial
33
Non obstructive coronary ischemia
Endothelial dysfunction and or VSMC hyperreactivity (autonomic dysfunction)
34
Vasomotor function
Important in determining cause for ischemia
35
Testing for cad
PET/SPECT structure and function CMR structure & function CORONARY CT angiography
36
CTA coronary angiography allows
Coronary calcification % stenosis in epicardial coronaries Congenital coronaries Intramyocardial bridging Bypass grafts
37
CTA angiography also help
FRACTIONAL FLOW RESERVE (functional assessment)
38
CTA to assess coronary fractional flow reserve
FFR value <0.8 is abnormal
39
PET SCAN HELPS W
Myocardial flow reserve
40
PET CT coronaries
Myocardial flow reserve < 2 predicts all cause mortality
41
Afib
Cha2ds-vasc equal to or > 2 in men, use anticoagulant Cha2dsvasc equal to or >3 in women, use doac
42
Pulse field ablation
Afib
43
ARNI first line Decrease in death, increase EF, decrease readmission rates
44
Alternativa to ARNI
Hydralazine/isosorbide dinitrate (start 20 mg each) Hydralazine 100 mg/ isosorbide 40 mg
45
Hold diuretic if you start ARNI
46
Start mineral corticoid antagonist i
Men creatinine is <2.5 Women creatinine 2
47
SGLT2 inhibitors EMPA -Reg outcomes NEJM 2015:373:2117-28
Female patients had more UTI in placebo group Male same Except mycotic infection
48
Diuretic adjuncts
Acetazolamide 500 mg iv daily Metolazone 5 mg or chlorothiaxidd 500 Remember to bolud.
49
CVP= J P + 5 cm
CVP = JVP + 5 cm
50
ARNI RELATIVE RISK REDUCTION 42%
JAMA Cardiology 2021:6(7):743-744
51
Metotolol succinate
52
ARNI GIRST LINE
Hydralazinr ISDN 50
53
Stop diuretic when start ARNI
54
After one year after stent, do not add aspirin to pts on DOAC/ac
Circulation 2023 Aug29:148(9):e9-e119
55
Mimics of HFpEF R/o valvular disorder Congenital heart disease
Cardiac amyloid Cor pulmonale High output syndrome Hypertrophic cardiomyopathy Infiltrative disorder Ischemic heart disease Pulmonary HTN Storage disorder
56
HFrEF
Congestion: start ARNI and SHLT2 inhibitions Low blood pressure: MRA, SGLT2 inhibe Patients at risk for hyperKALEMIA, start ARNI, SGLT2